Integrated Medical Affairs
Scientific communication with impact.
We build strong relationships and engaging conversations delivering your core value messaging to medical stakeholders with influence.
How can we help?
How can we help?
Early development of a clear medical engagement strategy is key to driving launch success in rare disease and specialty care products.
We develop medical strategies that cover content, key congresses, stakeholder engagement, and channel tactics. We apply state-of-the-art market intelligence to map the field of medical stakeholders and potential centers of excellence in our partners’ target indication. Additionally, we tailor geography-appropriate medical strategies that connect clinical evidence and core value messages in the most impactful way.
We believe that eye-level conversations and the human touch stands out among the constant stream of communication that targets medical stakeholders.
We first establish relationships in the physical world, then utilize virtual direct visits to provide more impactful insights towards the medical and patient advocacy communities.
Through our engagements, we give a voice to our stakeholders and provide our partners with the opportunity to gain valuable real-world insights on clinical practice, unmet medical needs, and user sentiment affecting the success of their product(s). Our medical engagement activities have been successful in fostering strong networks and long-term collaborations within oncology, hematology, metabolic disease, and other key therapeutic areas.
Choosing the right forum to share clinical developments or collect stakeholder feedback can be challenging.
From scientific advisory boards and intimate roundtable discussions – to planning and executing on regional congress sponsorships and general awareness events – we work closely with our partners to build event schedules that align available resources with development objectives.
Regardless of the development stage, we keep your target audience engaged through impactful communications.
Offerings across the drug life cycle
Phase 1 & 2
Expansion & maturity
Contact our Medical Affairs experts today!